Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate

US Government Drug Pricing ‘Negotiation:’ Where We Go From Here

House passes Democratic bill authorizing the federal government to negotiate drug prices in Medicare. While the exercise has sharpened the debate over how prices feed innovation, the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Our table highlights the key provisions of HR 3 and other pending pricing legislation.

Pricing Debate Legislation Reimbursement

Latest From Pricing Debate

Drug Industry Perks Mostly Dropped From COVID-19 Bill, But A Big One Remains

Early versions of US Congress's coronavirus relief bill contained a number of policies that would have benefited drug firms, but they didn't make it into the final bill. However, the $2 trillion package does provide pharmaceutical companies with relief from the threat of drug pricing reform until after the 2020 elections.

Coronavirus COVID-19 Pricing Debate

Countries Consider Pandemic Pooling of Rights And Compulsory Licensing

Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.

South America Chile

Drug Pricing Reform In 2020 Gets Harder Due To Third Coronavirus Bill

Senate and House versions of a pending coronavirus stimulus package take off the table a key legislative vehicle lawmakers planned to use to push for bipartisan drug pricing reform until at least after the 2020 elections, signaling a potential reprieve for the pharmaceutical industry. 

Coronavirus COVID-19 Legislation

Transition Day In The US: 96 Drugs Make The Move To Biologics Regulation

Sanofi’s Lantus stands alone as the only insulin product still listed in the ‘Orange Book’ post-transition because it is referenced in Mylan/Biocon’s pending 505(b)(2) application for insulin glargine; the FDA said it stands ready to review biosimilar and interchangeable applications that reference the newly ‘deemed’ biologic products.

Biologics Biosimilars

Pricing Reforms Prompt Canadian Business Rethink

The R&D based pharmaceutical industry would welcome changes to guidelines that will operationalize controversial new pricing regulations in Canada but industry experts say more is needed.

Canada Market Access

Canada To Rethink Controversial Pricing Rules

Canadian pricing body, the PMPRB, is considering relaxing screening criteria for drugs that will be subject to stricter price controls and extending grace periods for conforming with new rules.

North America Canada

Leng & Nebhrajani: New Chief & Chair For England’s NICE

The two top positions at UK health technology assessment body NICE have been filled.

United Kingdom Health Technology Assessment

Medicare Could Save More than $80bn With Price Inflation Rebates – CBO Score of Senate Bill

Nearly $70bn in savings over 10 years is expected to result from mandatory price inflation rebates for drugs covered by Medicare Part D.

Pricing Debate Legislation

Medicare Plan For Lowering Insulin Costs Takes Aim At Benefit Design Instead Of List Prices

The new payment demonstration in Part D reflects the increasing recognition that insurance benefit design has a major impact on insulin affordability.

Reimbursement Medicare
See All
UsernamePublicRestriction

Register